← All trials
NCT05076513
Early Phase 1Interventional
Exploratory trials, involving very limited human exposure, with no therapeutic or diagnostic intent (e.g., screening studies, microdose studies).
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2021
- Primary completion
- Oct 31, 2022
- Completion date
- Oct 31, 2024
- First posted
- Oct 13, 2021
- Last posted
- Nov 1, 2021
- Enrollment
- 42
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Barrow Neurological InstituteLead sponsor
- GlaxoSmithKlineCollaborator
- University of California, San FranciscoCollaborator
- University of ArizonaSponsor investigator
- Barrow Neurological InstituteCollaborator
- Ivy Brain Tumor CenterCollaborator
- Ivy Brain Tumor CenterOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.